Large contract wins set up Q2 momentum test—watch order execution pace
Avantel enters Q2 results on the back of three major contract awards (Zetwerk ₹177 Cr, DRDO ₹117.88 Cr, L&T orders) and Q1's exceptional profit growth (+67% YoY). The Street expects sustained momentum, but valuation at 320x earnings demands flawless execution.
The headline: revenue momentum, but profit quality matters most
Avantel reported Q1 FY-2027 consolidated revenue of ₹70.42 Cr (+35.6% YoY, +10.3% QoQ) and net profit of ₹5.39 Cr (+67.1% YoY). The profit surge outpaced revenue growth, signalling margin expansion. For Q2, the on-plan expectation is revenue in the ₹85–95 Cr range (applying 30–35% YoY growth—consistent with Q1 and the order-book visibility) and profit in the ₹6–7 Cr range (30%+ YoY growth). A strong Q2 would hold margins steady while executing on the large contracts awarded in August–September; a weak Q2 would show slowing revenue growth or margin compression from execution pressure or project mix shifts.
~₹85–95 Cr
30–35% YoY growth; Q1 set ₹70.42 Cr baseline
~₹6–7 Cr
30%+ YoY growth; margin stability key
Zetwerk ₹177 Cr, DRDO ₹117.88 Cr
Awarded Aug–Sep; phased delivery; visibility into H2 FY-27
+98 bps QoQ
1.53% in Q1 FY27 vs 0.55% in Q4 FY26; subtle buy signal
On track with full-year guidance?
Prior guidance for FY-2027 is not yet disclosed in our records; the Board will likely comment on full-year expectations during the results call. However, the trajectory is visible: Q1 showed strong organic growth and improved operating leverage. The large contract awards (Zetwerk, DRDO, L&T) provide clear visibility into order execution for H2, suggesting the company is well-positioned to sustain 30%+ revenue growth for the fiscal year. The merger of Imeds Global (approved Sep 18) is a strategic step to consolidate operations, though integration costs should be watched in H2. If Q2 confirms the Q1 run-rate and management guides to full-year revenue growth of 25–30%, the market will likely re-rate the stock upward.
What the Street says
Since last quarter: large contracts and strategic moves
1 · Zetwerk contract (Sep 23): ₹177.35 Cr
Major purchase order from Zetwerk Manufacturing for supply of components/services, pursuant to an earlier awarded rate contract. This order, sized at ₹177.35 Cr, is one of the largest single awards and signals ongoing capacity utilization in Q2–Q3.
2 · DRDO contract (Aug 29): ₹117.88 Cr
Significant defence contract from DRDO (Ministry of Defence) for ground segment hub services, valued at ₹117.88 Cr. This order underscores Avantel's positioning in satellite and defence infrastructure.
3 · L&T orders (Jul–Oct): ₹20.81 Cr + ₹12.04 Cr
Incremental orders from Larsen & Toubro for SATCOM products and annual maintenance, totalling ~₹33 Cr. Routine but steady stream of business; signals stable operating relationships.
4 · Imeds Global merger (Sep 18): Wholly-owned subsidiary merged
Board approved the merger of subsidiary Imeds Global into the parent, along with MoA alteration. This is a consolidation move; integration costs should be monitored in H2, but synergies (if any) may benefit FY-2028 onwards.
5 · FII inflow: +98 bps QoQ
FII ownership increased from 0.55% in Q4 FY26 to 1.53% in Q1 FY27. DII also raised position by 22 bps. Promoter holding stable at 37.04%. The inflows suggest institutional validation of the growth story, though absolute ownership is still modest.
What to watch on Oct 26
The Board will convene on Oct 26 to approve Q2 FY-2027 unaudited results. The key metrics to scrutinize: (1) Revenue growth rate—does the company maintain 30%+ YoY momentum, or has the pace slowed? (2) Operating margin—with the large contracts underway, are margins holding, or is execution eating into profitability? (3) Order backlog visibility—management's commentary on H2 execution and any new awards post-Zetwerk/DRDO. (4) Working capital and cash flow—large contracts often demand upfront capex; any balance-sheet stress? (5) Imeds integration update—timeline and cost synergy expectations. (6) Full-year FY-2027 guidance—if disclosed, this will be the biggest re-rating catalyst or risk.
Avantel's Q2 earnings arrive at an inflection point. Q1 delivered exceptional profit growth (+67% YoY) and the company has since landed three major contract wins totalling ~₹318 Cr. The Street expects the momentum to persist, with an analyst consensus of Buy and a ₹205 target. However, valuation at 320x earnings leaves no room for execution stumbles. The preview sets up a simple equation: if Q2 confirms the on-plan revenue run-rate (₹85–95 Cr) and margins hold steady, the stock has a clear path to re-rate. If execution falters—whether from supply-chain delays, margin pressure, or order deferrals—the valuation multiples could compress sharply. Management's tone on H2 visibility and capex requirements will be the deciding tone for near-term sentiment.
Informational and educational content only. Not investment advice.